Overview
2. Epidemiologic studies to better understand the causes and variability in prognosis of amyotrophic lateral sclerosis and diabetic neuropathy.
3. Basic science studies to develop novel biomarkers for amyotrophic lateral sclerosis.
Current Appointments & Affiliations
Stewart, Hughes and Wendt Distinguished Professor
·
2023 - Present
Neurology, Neuromuscular Disease,
Neurology
Professor of Neurology
·
2018 - Present
Neurology, Neuromuscular Disease,
Neurology
Faculty Network Member of the Duke Institute for Brain Sciences
·
2011 - Present
Duke Institute for Brain Sciences,
University Institutes and Centers
Associate of the Duke Initiative for Science & Society
·
2017 - Present
Duke Science & Society,
University Initiatives & Academic Support Units
Recent Publications
Author Response: Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.
Journal Article Neurology · November 11, 2025 Full text Link to item CiteALSUntangled #81: Pyridostigmine (mestinon®).
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · November 6, 2025 Pyridostigmine (Mestinon®, Bausch Health, Canada Inc.) increases acetylcholine availability at the neuromuscular junction, enhancing transmission. Preclinical studies suggest that neuromuscular junction dysfunction develops early in ALS, and pyridostigmine ... Full text Link to item CiteALSUntangled #80: ISRIB (Integrated stress response InhiBitor).
Journal Article Amyotroph Lateral Scler Frontotemporal Degener · November 2025 ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we assess ISRIB, a molecule that attenuates the integrated stress response (ISR). The ISR is an intracellular signaling network thro ... Full text Link to item CiteRecent Grants
SEA-NOBI-ALS
Clinical TrialPrincipal Investigator · Awarded by WideTrial, Inc. · 2025 - 2028Pridopine EAP 2 (Clinical Site Agreement)
ResearchPrincipal Investigator · Awarded by Massachusetts General Hospital · 2024 - 2027A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS
Clinical TrialPrincipal Investigator · Awarded by MediciNova, INC. · 2020 - 2026View All Grants
Education, Training & Certifications
University of Connecticut ·
1995
M.D.
University of Connecticut ·
1995
Ph.D.